Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(25%)
Results Posted
25%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_1
7
88%

Phase Distribution

7

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
80.0%
Most Advanced
Phase 1

Trials by Phase

Phase 17 (87.5%)
N/A1 (12.5%)

Trials by Status

terminated113%
active_not_recruiting225%
withdrawn113%
completed450%

Recent Activity

2 active trials
Showing 5 of 8
active_not_recruitingphase_1

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

NCT02726711
active_not_recruitingphase_1

Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension

NCT02425566
terminatedphase_1

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

NCT02245230
withdrawnphase_1

Autonomic Blockade and Endogenous Glucose Production

NCT03028571
completedphase_1

The Autonomic Nervous System and Obesity

NCT00179023
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02726711Phase 1

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

Active Not Recruiting
NCT02425566Phase 1

Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension

Active Not Recruiting
NCT02245230Phase 1

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Terminated
NCT03028571Phase 1

Autonomic Blockade and Endogenous Glucose Production

Withdrawn
NCT00179023Phase 1

The Autonomic Nervous System and Obesity

Completed
NCT01137253Phase 1

Autonomic Nervous System and Nitric Oxide Interactions

Completed
NCT01122407Phase 1

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Completed
NCT00178919Not Applicable

Nitric Oxide and the Autonomic Nervous System

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8